Descrizione del progetto
Un dispositivo per trattare le complicanze successive alla cardiochirurgia
Dopo un intervento chirurgico al cuore, molti pazienti sviluppano fibrillazione atriale postoperatoria, un tipo di aritmia che accresce di quasi tre volte il rischio di ictus. Per evitare l’uso di farmaci, il progetto DefiPace-System, finanziato dall’UE, porterà sul mercato un dispositivo che agevola la prevenzione e il trattamento della fibrillazione atriale postoperatoria nei pazienti sottoposti all’intervento. Il dispositivo aiuta il cuore a ripristinare il suo ritmo fisiologico attraverso un processo noto come stimolazione bi-atriale, senza necessità di anestesia. Ma ancor più importante, si tratta di un dispositivo portatile, facile da usare e che può essere impiegato dal personale medico nel reparto generico di qualsiasi ospedale.
Obiettivo
The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a
significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently
occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and
duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons
results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable
ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our
new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative
atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing
as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers
are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing &
cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar
to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF •
Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings
for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication
required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for
OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second
time in our history
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME-2b - SME Instrument (grant only and blended finance)Coordinatore
79618 Rheinfelden Baden
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.